Nucleix
Business Services · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
20 Hasatat St, Modi'in, 7171101, IsraelPhone Number
(858) 283-3398Website
www.nucleix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Nucleix
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS and PCR-based epigenetics, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company's non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck® testing kit, marketed in Europe for bladder cancer recurrence. The Company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases.Explore more
Nucleix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nucleix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nucleix
Check if Nucleix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nucleix recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Nucleix is spiking on competitors!
Click to see if Nucleix had a recent Job posting/layoffs
Product Launch: Get notified when Nucleix launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Nucleix, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Nucleix has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Nucleix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nucleix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nucleix.
Nucleix financials insights
Gather financial insights about Nucleix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$5M
2016
Unspecified
$3M
2021
Other Financing Round
$55M
2022
Other Financing Round
$22M
Nucleix Tech Stack
A closer look at the technologies used by Nucleix
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
Funding
Funding
Nucleix News & Media
A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). FLORENCE, Italy, Sept. 9, 2024 /PRNewswire/ -- A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutiA. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract...A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract...A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe
FLORENCE, Italy & SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. This non-invasive CE-marked test d
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nucleix
Sign Up For FreeTo access detailed company insights
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS and PCR-based epigenetics, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Compa... Read More
